Navigation Links
Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
Date:12/9/2010

SANTA ROSA, Calif., Dec. 9, 2010 /PRNewswire/ -- Osseon Therapeutics, Inc. today named Mr. Gary Coughlen, CPA as the company's Chief Financial Officer, effective immediately.

Mr. Coughlen was most recently the Chief Financial Officer of PolyRemedy, Inc., a private-equity medical device company focused on wound care management. Prior to PolyRemedy, he served as the CFO of Refractec Inc., a manufacturer, and distributor of ophthalmic surgical devices to the global market. Coughlen started in 1999 at the founder's stage with three employees and served as Refractec's CFO through its growth to 75 employees.  

Earlier in his career, Coughlen served as CFO at Scieran Technologies, Inc and was a Vice President at Sierra Capital. He began his career in the public accounting at PricewaterhouseCoopers.

"I'm looking forward to the opportunities ahead for Osseon," said Coughlen. "We have an incredible pipeline of products, a solid distribution plan and we are well-positioned for growth."

"Gary brings outstanding expertise to Osseon," said John Stalcup, Ph.D., CEO and President. "He has a broad range of experience in senior financial management positions with medical device companies, and an extensive background in the equity and debt capital markets. We welcome him to our leadership team and look forward to his contributions to Osseon."

Coughlen is a graduate of University of Washington, where he earned a bachelor's degree in Business Administration and UC-Berkley where he completed his Masters in Business Administration.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease.  Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them.  Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.  For more information, visit our web site at www.osseon.com.

Osseon is a registered trademark of Osseon Therapeutics, Inc.

The names of actual companies and products mentioned herein may be the trademarks of their respective owners.


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):